Cancer Immunology, Immunotherapy

, Volume 61, Issue 9, pp 1463–1472 | Cite as

Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer

  • Sandra Salvi
  • Vincenzo Fontana
  • Simona Boccardo
  • Domenico Franco Merlo
  • Edoardo Margallo
  • Stefania Laurent
  • Anna Morabito
  • Erika Rijavec
  • Maria Giovanna Dal Bello
  • Marco Mora
  • Giovanni Battista Ratto
  • Francesco Grossi
  • Mauro Truini
  • Maria Pia Pistillo
Original article

Abstract

The role of CTLA-4 in negative regulation of T-cell mediated immune response is particularly well established. Much less is known about its expression and function in tumour cells, and to our knowledge, no data are available on its possible impact on prognosis of NSCLC patients. We investigated CTLA-4 expression and prognostic role in 81 patients with radically resected stage I–III NSCLC. The analysis was performed by tissue microarray immunohistochemistry, and the median H-score of 20 was used as a threshold to define CTLA-4 overexpressing tumours. Correlation with standard prognostic factors was performed by using absolute and relative fold change indexes. Hazard ratios (HR) and corresponding 95% confidence limits (95% CL) were computed through the Cox model. A higher frequency of CTLA-4 overexpression (>20) was found in non-squamous than in squamous NSCLC (52.8 vs. 35.7%) and in Ki67 ≤ 15 expressing tumours, as compared to those with Ki67 > 15 (51.5 vs. 38.7%). A reduced death rate was found in CTLA-4 overexpressing tumours (HR = 0.60, 95% CL = 0.28/1.23), and a further decrease was observed when considering tumours with CTLA-4 > 20 and Ki67 ≤ 15, in comparison with tumours with CTLA-4 ≤ 20 and Ki67 > 15 (HR = 0.41; 95% CL = 0.15/1.13). Our observational and exploratory study provides a first and promising indication for an independent prognostic effect of CTLA-4 overexpression in radically resected NSCLC. We presume that this effect relies on modulation of the interaction of microscopic disease with CTLA-4-ligands expressing cells leading to NSCLC cell death.

Keywords

CTLA-4 Immunohistochemistry Non-small cell lung cancer Overall survival Prognostic factor 

References

  1. 1.
    Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533–2540PubMedCrossRefGoogle Scholar
  2. 2.
    Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP (1999) CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 162:5813–5820PubMedGoogle Scholar
  3. 3.
    Teft WA, Kirchhof MG, Madrenas J (2006) A molecular perspective of CTLA-4 function. Annu Rev Immunol 24:65–97PubMedCrossRefGoogle Scholar
  4. 4.
    Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J et al (2000) CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 165:1352–1356PubMedGoogle Scholar
  5. 5.
    Jain N, Nguyen H, Chambers C, Kang J (2010) Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci USA 107:1524–1528PubMedCrossRefGoogle Scholar
  6. 6.
    Merlo A, Tenca C, Fais F, Battini L, Ciccone E, Grossi CE, Saverino D (2005) Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin Diagn Lab Immunol 12:705–712PubMedGoogle Scholar
  7. 7.
    Wang XB, Giscombe R, Yan Z, Heiden T, Xu D, Lefvert AK (2002) Expression of CTLA-4 by human monocytes. Scand J Immunol 55:53–60PubMedCrossRefGoogle Scholar
  8. 8.
    Laurent S, Carrega P, Saverino D, Piccioli P, Camoriano M, Morabito A et al (2010) CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions. Hum Immunol 71:934–941PubMedCrossRefGoogle Scholar
  9. 9.
    Kaufman KA, Bowen JA, Tsai AF, Bluestone JA, Hunt JS, Ober C (1999) The CTLA-4 gene is expressed in placental fibroblasts. Mol Hum Reprod 5:84–87PubMedCrossRefGoogle Scholar
  10. 10.
    Nagaraju K, Raben N, Villalba ML, Danning C, Loeffler LA, Lee E et al (1999) Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 92:161–169PubMedCrossRefGoogle Scholar
  11. 11.
    Pistillo MP, Tazzari PL, Palmisano GL, Pierri I, Bolognesi A, Ferlito F et al (2003) CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 101:202–209PubMedCrossRefGoogle Scholar
  12. 12.
    Joshi AD, Hegde GV, Dickinson JD, Mittal AK, Lynch JC, Eudy JD et al (2007) ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res 13:5295–5304PubMedCrossRefGoogle Scholar
  13. 13.
    Kosmaczewska A, Ciszak L, Suwalska K, Wolowiec D, Frydecka I (2005) CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients. Leukemia 19:301–314PubMedCrossRefGoogle Scholar
  14. 14.
    Mao H, Zhang L, Yang Y, Zuo W, Bi Y, Gao W et al (2010) New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets 10:728–736PubMedCrossRefGoogle Scholar
  15. 15.
    Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Falà F, Fabbi M et al (2005) CTLA-4 is constitutively expressed on tumour cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538–550PubMedCrossRefGoogle Scholar
  16. 16.
    Shah KV, Chien AJ, Yee C, Moon RT (2008) CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumours. J Invest Dermatol 128:2870–2879PubMedCrossRefGoogle Scholar
  17. 17.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 19(363):711–723CrossRefGoogle Scholar
  18. 18.
    Tarhini A, Lo E, Minor DR (2010) Releasing the brake on the immune system: ipilimumab in melanoma and other tumours. Cancer Biother Radiopharm 25:601–613PubMedCrossRefGoogle Scholar
  19. 19.
    Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumour immunity by CTLA-4 blockade. Science 27:1734–1736CrossRefGoogle Scholar
  20. 20.
    Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL et al (2005) Tumour regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12:1005–1016PubMedCrossRefGoogle Scholar
  21. 21.
    Page DB, Yuan J, Wolchok JD (2010) Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy 2(3):367–379PubMedCrossRefGoogle Scholar
  22. 22.
    Zheng H, Li Y, Wang X, Zhang X, Wang X (2010) Expression and significance of gp96 and immune-related gene CTLA-4, CD8 in lung cancer tissues. Zhongguo Fei Ai Za Zhi 13:790–794PubMedGoogle Scholar
  23. 23.
    Naruke T, Suemasu K, Ishikawa S (1978) Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 76:832–839PubMedGoogle Scholar
  24. 24.
    Sobin LH, Wittekind CH (eds) (1997) TNM classification of malignant tumours, 5th edn. Wiley-Liss, New York, pp 59–62Google Scholar
  25. 25.
    Sobin LH and Pathologists from 14 Countries World Health Organization International Histological Classification of Tumours (1999) Histological typing of lung and pleural tumours, 3rd edn. Springer, GenevaGoogle Scholar
  26. 26.
    Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M (2006) Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res 1(12):3971–3978CrossRefGoogle Scholar
  27. 27.
    Dertsiz L, Ozbilim G, Kayisli Y, Gokhan GA, Demircan A, Kayisli UA (2005) Differential expression of VASP in normal lung tissue and lung adenocarcinomas. Thorax 60:576–581PubMedCrossRefGoogle Scholar
  28. 28.
    Hosmer D, Lemeshow S (1999) Applied survival analysis: regression modeling of time to event data. Wiley, New YorkGoogle Scholar
  29. 29.
    Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127:469–480PubMedCrossRefGoogle Scholar
  30. 30.
    Bienz M (2005) Beta-catenin: a pivot between cell adhesion and Wnt signalling. Curr Biol 15:R64–R67PubMedCrossRefGoogle Scholar
  31. 31.
    Gavert N, Ben-Ze’ev A (2007) Beta-catenin signaling in biological control and cancer. J Cell Biochem 102:820–828PubMedCrossRefGoogle Scholar
  32. 32.
    Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Yokomise H (2001) E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg 71:949–955PubMedCrossRefGoogle Scholar
  33. 33.
    Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K (2000) Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 6:4789–4796PubMedGoogle Scholar
  34. 34.
    Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715PubMedGoogle Scholar
  35. 35.
    Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP et al (2004) Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91:2018–2025PubMedCrossRefGoogle Scholar
  36. 36.
    Zou W, Chen L (2005) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8:467–477CrossRefGoogle Scholar
  37. 37.
    Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515–548PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Sandra Salvi
    • 1
  • Vincenzo Fontana
    • 2
  • Simona Boccardo
    • 1
  • Domenico Franco Merlo
    • 2
  • Edoardo Margallo
    • 1
  • Stefania Laurent
    • 3
  • Anna Morabito
    • 3
  • Erika Rijavec
    • 4
  • Maria Giovanna Dal Bello
    • 4
  • Marco Mora
    • 1
  • Giovanni Battista Ratto
    • 5
  • Francesco Grossi
    • 4
  • Mauro Truini
    • 1
  • Maria Pia Pistillo
    • 3
  1. 1.Department of PathologyIRCCS A.O.U. San Martino-ISTGenoaItaly
  2. 2.Unit of Epidemiology, Biostatistics and Clinical TrialsIRCCS A.O.U. San Martino-ISTGenoaItaly
  3. 3.Tumour Genetics and EpigeneticsIRCCS A.O.U. San Martino-ISTGenoaItaly
  4. 4.Lung Cancer UnitIRCCS A.O.U. San Martino-ISTGenoaItaly
  5. 5.Unit of Thoracic SurgeryIRCCS A.O.U. San Martino-ISTGenoaItaly

Personalised recommendations